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ar, Santa Rosa, California).
ackground Early studies found that the drug-eluting stent (DES) was a clinically and economically
ttractive alternative to the bare-metal stent; however, associations between DES and very late stent
hrombosis suggest that longer follow-up is required.
ethods We used clinical, resource use and follow-up data from 1,197 subjects randomized to receive
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ng at a 3% annual rate, there were no differences in quality-adjusted survival days (1,093 vs. 1,090;
ifference: 3; 95% CI: 13 to 19; p  0.69) and total medical costs ($21,483 vs. $21,680; difference:
$198; 95% CI: $1,608 to $1,207; p  0.78).
onclusions The use of Endeavor versus Driver was associated with a signiﬁcant reduction in target
essel revascularization through 4-year follow-up with no difference in death, nonfatal myocardial
nfarction, quality-adjusted survival, or total medical costs. These results are comparable to those for
ther studies evaluating drug-eluting versus bare-metal stents. (Randomized Controlled Trial to Eval-
ate the Safety and Efﬁcacy of the Medtronic AVE ABT-578 Eluting Driver Coronary Stent in De Novo
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1179he introduction of bare-metal stents (BMS) in the mid-
990s successfully reduced short-term percutaneous coro-
ary intervention (PCI) repeat revascularization rates at an
cceptable cost to society (1,2). Drug-eluting stents (DES)
ere designed to further reduce repeat revascularization
ates by delivering medications that suppress neointimal
yperplasia, the principal cause of restenosis (3). Early
linical trials of DES versus BMS reported significant
See pages 1188 and 1236
eductions in restenosis rates to 1 year, and DES appeared
o be a clinically and economically attractive alternative to
MS (4–7). However, an association between DES use and
ery late stent thrombosis (1 year) was undetected in early
ssessments of short-term restenosis rates, suggesting that
onger follow-up periods may be required (8,9).
The ENDEAVOR II (Randomized Controlled Trial to
valuate the Safety and Efficacy of the Medtronic AVE
BT-578 Eluting Driver Coronary Stent in De Novo
ative Coronary Artery Lesions) study was a randomized,
ontrolled, clinical trial that compared the Endeavor
otarolimus-eluting stent (ZES) to the Driver bare cobalt-
hromium metal alloy stent (BMS) (both Medtronic Cardio-
ascular, Santa Rosa, California) (10). We evaluated long-
erm clinical and economic outcomes associated with the
se of ZES versus BMS using 4-year follow-up information
rom the ENDEAVOR II clinical trial. Our objectives were to
ompare differences in: 1) clinical event rates and survival
uration; 2) medical resource use and medical costs; and 3)
isease-specific cost-effectiveness (incremental medical costs
er target vessel revascularization [TVR] avoided) and com-
rehensive cost-effectiveness (incremental medical costs per
uality-adjusted life-year [QALY] saved) for subjects receiving
ES versus BMS.
ethods
atient population and treatment protocol. Between July
4, 2003, and January 13, 2004, the ENDEAVOR II
linical trial randomly assigned 1,197 subjects to receive
ES (n  598) or BMS (n  599) of whom 1,167 (ZES 
83, BMS  584) were followed for 4 years (10–12).
ubjects were included if they had clinical evidence of
schemia or an abnormal functional study and were under-
oing intracoronary stenting in a single, untreated, native
oronary artery. The primary study end point was target
essel failure (TVF) at 9-month follow-up—a composite of
VR, recurrent nonfatal myocardial infarction (MI) (both
- and non–Q-wave), or cardiac death not attributable to a
ontarget vessel. At the 270-day follow-up, fewer subjects
eceiving ZES versus BMS experienced TVF (7.9% vs.
5.1%; 7.1% difference; p  0.001), with TVR being the crimary TVF component contributing to this difference
5.6% vs. 12.5%; 6.9% difference; p  0.001).
ong-term clinical and economic analysis overview. Although
he ENDEAVOR II trial showed a clear reduction in TVF
nd TVR for subjects randomized to ZES versus BMS, the
ong-term clinical and economic implications of these results
ere uncertain. Our analysis included unpublished 4-year
ollow-up results from the ENDEAVOR II clinical trial. The
nalysis had 2 components: 1) an intention-to-treat analysis to
valuate clinical and economic outcomes for ZES versus BMS;
nd 2) a cost-effectiveness analysis to extend the intention-to-
reat results by combining clinical and economic outcomes to
stimate medical cost versus health benefit trade-offs (disease
pecific and comprehensive) for ZES versus BMS in the study
opulation. The ENDEAVOR
I protocol was approved by each
ite’s institutional review board
nd the long-term clinical and
conomic analysis protocol was
pproved by Duke University
edical Center’s Institutional
eview Board. All study subjects
onsented to participate in the
NDEAVOR II clinical trial.
ntention-to-treat analysis. Re-
earch coordinators completed
ase report forms documenting
ach subject’s baseline clinical
haracteristics, index procedure
esource use, clinical events, se-
ious adverse events (SAEs), and
dverse events. Major adverse
ardiac events (MACE) were
djudicated from ENDEAVOR
I clinical data by an indepen-
ent clinical events committee
hose members were blinded to
reatment assignment. We iden-
ified clinical and economic
vents from MACE, SAE, and
dverse events data using a hierarchy-of-evidence approach.
he MACE events were considered the highest level of
vidence. The SAE records were used as a secondary
vidence source to define other types of cardiac and non-
ardiac hospital stays not included in MACE records. The
AE hospitalization records were matched with adverse
vents records, which were the source for event start and
top dates, organ system (to differentiate cardiac from
oncardiac hospital stays), and Medical Dictionary for Reg-
latory Activities’s preferred terms (used to describe cardiac
ospital stays for medical cost assignment).
We developed an automated procedure whereby MACE
nd hospital stays were collapsed into unique episodes of
Abbreviations and
Acronyms
BMS  bare-metal stent(s)
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
DES  drug-eluting stent(s)
DRG  diagnosis-related
group
MACE  major adverse
cardiac events
MI  myocardial Infarction
PCI  percutaneous
coronary intervention
QALY  quality-adjusted
life-year
SAE  serious adverse
events
TVF  target vessel failure
TVR  target vessel
revascularization
ZES  zotarolimus-eluting
stent(s)are (1 index procedure per subject and a variable number of
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1180ollow-up episodes). Except for deaths outside a hospital
outpatient deaths), all episodes of care were associated with
n inpatient stay. Diagnosis-related groups (DRGs) were
ssigned to episodes of care using the logic of the CMS
S-DRG Grouper (Centers for Medicare and Medicaid
ervices, Baltimore, Maryland) and audited by a medical
ecords professional (13). Medical costs for all episodes of
are were estimated using 2008 Medicare national average
ayment amounts (calculated using an average hospital
edicare base rate of $4,893) (14,15). Medical costs and
rithmetic mean lengths of stay for cardiovascular episodes
f care were estimated by DRG; whereas, estimates for
oncardiovascular episodes of care were assigned using a
ational average relative weight. Costs for physician services
ere estimated using published sources to determine DRG-
pecific amounts and were adjusted to 2008 values using the
edical care component of the consumer price index (16).
s ZES and BMS stent costs are not specifically included in
edicare’s payment amounts for DES DRGs, the average
008 unit costs for the ZES ($2,100) and BMS ($900) were
dded to Medicare’s reimbursement amounts for balloon
ngioplasty procedures (data on file, Medtronic CardioVas-
Table 1. Index Procedure Clinical Characteristics and
Clinical Characteristics
Age, median (25th, 75th percentiles), yrs
Female
Minority race
History of
Cigarette smoking prior year
Diabetes mellitus
Hyperlipidemia
Hypertension
Myocardial infarction
Any revascularization
Cardiac evaluation
Revascularization for angina or myocardial infarction
Number diseased vessels
Vessel count
Median (25th, 75th percentiles)
Mean (SD)
Resource use
Pre-treatment with PTCA
Number of stents implanted
Stent count
Median (25th, 75th percentiles)
Mean (SD)
0
1
2
Post-procedural LOS, median (25th, 75th percentiles)
LOS length of stay; PTCA percutaneous transluminal coronary anular). Because the ENDEAVOR II case report forms did cot stipulate type of repeat PCI procedure, we assumed a
istribution of 13% balloon angioplasty, 19% BMS, and
8% DES, based on the distribution of repeat PCI proce-
ures at Duke University Medical Center during the early
ES era (17).
We used previously defined methods to assign quality-
f-life estimates based upon clinical events occurring during
he study period (3). All study subjects received a 0.79
ALY adjustment for their index procedure year (4,5). A
ALY of 0.85, corresponding to having coronary artery
isease (CAD) was assigned to all years without a revascu-
arization; whereas, years with a revascularization were
ssigned a 0.79 QALY value. Subjects experiencing a
onfatal MI received a permanent 0.88 QALY adjust-
ent, and those with hospital stays received a QAL day
ecrement (0.0028 QALY) for each day’s length of stay
18).
TUDY OUTCOMES. Dual antiplatelet therapy use (aspirin,
lopidogrel, ticlopidine, and aspirin plus clopidogrel or
iclopidine) was evaluated at discharge; 30 days; and 6, 9,
2, 24, 36, and 48 months. Clinical outcomes included the
ollowing events: death, nonfatal MI, stroke, TVR (PCI,
urce Use
Driver
(n  599)
Endeavor
(n  598) p Value
63 (55, 70) 62 (54, 70) 0.67
7/599 (24.5) 136/598 (22.7) 0.46
8/599 (6.3) 36/598 (6.0) 0.82
7/588 (35.2) 207/587 (35.2) 0.98
2/595 (22.2) 108/595 (18.2) 0.08
5/592 (76.9) 476/591 (80.5) 0.12
3/591 (68.2) 378/596 (63.4) 0.08
7/595 (41.5) 236/594 (39.7) 0.53
8/599 (21.4) 151/598 (25.3) 0.11
3/596 (91.1) 545/597 (91.3) 0.91
0.73
1.0 (1.0, 2.0) 1.0 (1.0, 2.0)
1.5 (0.7) 1.5 (0.7)
0/596 (99.0) 589/597 (98.7) 0.59
0.60
1.0 (1.0, 1.0) (1.0, 1.0)
1.1 (0.3) 1.1 (0.3)
5/599 (0.8) 6/598 (1.0) 0.76
0/599 (88.5) 525/598 (87.8) 0.71
1/599 (10.2) 66/598 (11.0) 0.63
1.0 (1, 2) 1.0 (1, 2) 0.34
y.Reso
14
3
20
13
45
40
24
12
54
59
53
6oronary artery bypass graft [CABG] and total), non-TVR
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1181PCI, CABG, and total), total revascularizations (PCI,
ABG, and total), hospital stays (revascularization, other
ardiac, noncardiac, and total), survival days (with and
ithout quality-of-life adjustment, and with and without
iscounting at a 3% annual rate), and follow-up period total
ength of stay (19). The composite outcomes of death or MI
nd death or MI or TVR also were evaluated. Medical costs
Table 2. 4-Year Dual Antiplatelet Therapy Use
Anticoagulant
Driver
(n  599) (
At discharge
Aspirin 590/595 (99.2) 58
Clopidogrel 574/595 (96.5) 57
Ticlopidine 20/595 (3.4) 2
Dual therapy 589/595 (99.0) 58
At 30 days
Aspirin 563/584 (96.4) 57
Clopidogrel 546/584 (93.5) 55
Ticlopidine 20/583 (3.4) 2
Dual therapy 552/586 (94.2) 56
At 6 months
Aspirin 549/580 (94.7) 56
Clopidogrel 365/580 (62.9) 37
Ticlopidine 13/571 (2.3) 1
Dual therapy 359/580 (61.9) 37
At 9 months
Aspirin 539/580 (92.9) 55
Clopidogrel 244/579 (42.1) 26
Ticlopidine 11/577 (1.9)
Dual therapy 234/580 (40.3) 25
At 12 months
Aspirin 525/572 (91.8) 53
Clopidogrel 186/572 (32.5) 18
Ticlopidine 2/568 (0.4)
Dual therapy 166/572 (29.0) 16
At 24 months
Aspirin 519/562 (92.3) 52
Clopidogrel 96/555 (17.3) 9
Ticlopidine 1/551 (0.2)
Dual therapy 76/562 (13.5) 6
At 36 months
Aspirin 489/547 (89.4) 49
Clopidogrel 75/545 (13.8) 7
Ticlopidine 1/544 (0.2)
Dual therapy 50/548 (9.1) 4
At 48 months
Aspirin 484/546 (88.6) 48
Clopidogrel 74/544 (13.6) 7
Ticlopidine 1/544 (0.2)
Dual therapy 50/546 (9.2) 4
CI confidence interval.ere reported by time interval (first year, second year, third sear, and fourth year), and cumulative (with and without
iscounting at a 3% annual rate).
NTENTION-TO-TREAT ANALYSES. Index procedure clinical
haracteristics and resource use results are presented as
ercentages for discrete variables and as medians, 25th and
5th percentiles for continuous variables. Differences be-
ween dichotomous variables are assessed using the chi-
t Use
p Value
vor
98)
Difference
(95% CI)
(97.8) 1.3 (2.7 to 0.0) 0.094
(96.5) 0.0 (2.1 to 2.1) 1.000
(3.5) 0.2 (1.9 to 2.2) 1.000
(97.8) 1.2 (2.6 to 0.2) 0.164
(97.3) 0.9 (1.1 to 2.9) 0.409
(94.4) 0.9 (1.8 to 3.6) 0.542
(3.8) 0.3 (1.8 to 2.5) 0.875
(95.4) 1.2 (1.3 to 3.7) 0.361
(96.9) 2.2 (0.1 to 4.5) 0.079
(65.5) 2.5 (3.0 to 8.0) 0.391
(2.1) 0.2 (1.9 to 1.5) 1.000
(64.8) 2.9 (2.7 to 8.4) 0.330
(94.5) 1.6 (1.2 to 4.4) 0.279
(46.1) 4.0 (1.7 to 9.7) 0.174
(0.7) 1.2 (2.5 to 0.1) 0.074
(43.1) 2.7 (3.0 to 8.4) 0.372
(94.4) 2.6 (0.3 to 5.5) 0.102
(33.0) 0.5 (5.0 to 5.9) 0.900
(0.2) 0.2 (0.8 to 0.4) 1.000
(29.5) 0.5 (4.8 to 5.7) 0.897
(91.5) 0.8 (4.0 to 2.4) 0.663
(16.7) 0.6 (5.0 to 3.8) 0.811
(0.0) 0.2 (0.5 to 0.2) 0.497
(11.4) 2.1 (5.9 to 1.8) 0.322
(88.8) 0.5 (4.2 to 3.1) 0.773
(14.0) 0.2 (3.9 to 4.3) 0.931
(0.2) 0.0 (0.5 to 0.5) 1.000
(8.6) 0.5 (3.9 to 2.8) 0.833
(89.5) 0.8 (2.9 to 4.5) 0.698
(14.5) 0.9 (3.2 to 5.0) 0.726
(0.0) 0.2 (0.5 to 0.2) 1.000
(8.1) 1.0 (4.4 to 2.3) 0.590Percen
Endea
n  5
3/596
5/596
1/596
3/596
2/588
5/588
2/585
1/588
1/579
7/576
2/569
5/579
1/583
8/581
4/581
1/583
8/570
8/570
1/565
8/570
0/568
4/563
0/558
5/569
4/556
7/551
1/552
8/557
5/542
8/538
0/537
4/542quare statistic or Fisher exact test, and differences between
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1182ontinuous variables are assessed using the Kruskal-Wallis
est. Follow-up outcomes, hospital stays, survival days, and
edical costs are presented as cumulative values by treat-
ent with differences, 95% confidence intervals (CI), and p
alues. Medical costs also are presented within time periods
f interest (first year, second year, third year, fourth year,
nd cumulative). These analyses are performed on parti-
ioned data using generalized linear models with adjustment
or censoring and empirical standard errors (20,21). All
nalyses were performed with SAS software (version 8.2 or
igher, SAS Institute, Cary, North Carolina).
OST-EFFECTIVENESS ANALYSES. Two types of cost-
ffectiveness analyses were planned. However, the presen-
ation of these analyses as results was conditioned upon the
xistence of significant differences in the numerators and
enominators of these ratios. If these differences did not
xist, we would report their numerators and denominators
s separate values. First, because the primary clinical benefit
f DES versus BMS is a reduction in TVR procedures, we
ought to perform a disease-specific cost-effectiveness anal-
sis to evaluate the incremental medical costs per TVR
voided by dividing the difference in 4-year medical costs for
ubjects receiving the ZES versus BMS stents by the
ifference in TVR procedures over the same interval. A
econd, comprehensive cost-effectiveness analysis sought to
stimate the cumulative 4-year incremental total medical
osts per QALY saved with the use of ZES versus BMS
Table 3. 4-Year Clinical Outcomes
Outcomes
Death, %
Nonfatal MI, %
Stroke, %
Target vessel revascularizations (events per 100 subjects)
PCI
CABG
Total
Nontarget vessel revascularizations (events per 100 subjects
PCI
CABG
Total
Total revascularizations (events per 100 subjects)
Total PCI
Total CABG
Total
Composite outcomes, %
Death or MI
Death or MI or TVR
CABG coronary artery bypass graft; CI confidence interval; MIm
vessel revascularization.tent by dividing the difference in 4-year discounted medical Posts by the difference in discounted quality-adjusted sur-
ival. The variability of this estimate would be assessed
sing the nonparametric bootstrap procedure, with results
resented as mean values for the ratio (22,23). Incremental
edical costs, incremental quality-adjusted survival, and
omprehensive cost-effectiveness would be calculated with
nd without a 3% annual discount rate.
esults
ndex procedure. Patients receiving ZES and BMS stents
ere well-matched with regard to age, sex, and race (Table
). Most subjects underwent revascularization for angina or
I and nearly one-third had multivessel CAD. During
heir index procedure, most subjects received pre-treatment
ith balloon angioplasty and had a single stent implanted.
here were no instances of emergency bypass surgery and
he typical patient had 1-day post-procedural length of stay.
ual antiplatelet therapy. There were no treatment-related
ifferences in the use of dual antiplatelet therapy throughout
he 4-year follow-up period (Table 2). At discharge, more
han 95% of subjects receiving ZES and BMS had received
ual antiplatelet therapy. This declined to 50% at 9
onths and 10% in the third and fourth follow-up years.
-year outcomes. Over a 4-year follow-up period, the use of
ES versus BMS led to a significant reduction in TVR
rocedures that was driven largely by reductions in TVR with
Event Rates
p Value
Driver
n  599)
Endeavor
(n  598)
Difference
(95% CI)
5.2 5.0 0.2 (2.4 to 2.7) 0.90
4.4 3.2 1.2 (1.0 to 3.4) 0.29
1.5 1.7 0.2 (1.7 to 1.3) 0.81
19.8 9.8 10.0 (5.3 to 14.7) 0.001
1.7 0.7 1.1 (0.2 to 2.3) 0.097
21.5 10.4 11.1 (6.1 to 16.0) 0.001
15.4 17.8 2.4 (7.7 to 2.8) 0.36
1.9 1.0 0.9 (0.5 to 2.3) 0.21
17.3 18.8 1.5 (7.0 to 3.9) 0.58
33.3 26.2 7.1 (0.0 to 14.1) 0.049
2.4 1.2 1.2 (0.3 to 2.8) 0.11
35.7 27.4 8.3 (1.0 to 15.6) 0.025
9.0 7.9 1.2 (2.0 to 4.3) 0.47
24.4 15.3 9.1 (4.5 to 13.6) 0.001
al infarction; PCI percutaneous coronary intervention; TVR target(
)
yocardiCI (Table 3, Fig. 1). Treatment-related differences in TVR
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Figure 1. 4-Year Cumulative Events
4-year cumulative rates according to randomization to the Driver bare-metal stent versus the Endeavor drug-eluting stent for: (A) target vessel revasculariza-
tion, (B) nontarget vessel revascularization, (C) percutaneous coronary intervention revascularization, (D) coronary artery bypass graft surgery revascularization,
(E) death or myocardial infarction event, and (F) death or myocardial infarction or target vessel revascularization event.
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1184er 100 subjects continued to increase during the second
hrough fourth follow-up years (3.3 ZES vs. 6.4 BMS;
ifference:3.1; 95% CI:5.9 to 0.4; p 0.027). There were
o treatment-related differences in death, nonfatal MI, stroke,
on-TVR, or the composite of death or MI. However there
as a difference in the composite of death or MI or TVR.
-year other hospital stays. Subjects receiving ZES versus
MS stents tended to experience fewer revascularization
nd total hospital stays during the 4-year follow-up period
ith no difference in other cardiac and noncardiac hospital
tays (Table 4). These differences in hospitalization rates
ere associated with a nonsignificant difference in total
ength of stay.
-year quality-adjusted survival and medical costs. At 4-year
ollow-up, subjects receiving ZES versus BMS had greater
urvival and quality-adjusted survival and lower total med-
cal costs; however, none of these differences were statisti-
ally significant (Table 5). Whereas treatment-related
uality-adjusted survival curves did not diverge throughout
he 4-year study period, medical costs converged between
he index procedure and the end of the 4-year follow-up
Figs. 2 and 3).
Table 4. 4-Year Other Hospital Stays and Length of S
Driver
(n  599)
Other hospital stays (per 100 subjects)
Revascularization 35.4
Other cardiac 1.4
Noncardiac 101.9
Total 138.7
Total length of stay (days per subject) 6.3
CI confidence interval.
Table 5. 4-Year Quality-Adjusted Survival and Medica
Driver
(n  599)
Survival, days 1,405
Quality-adjusted survival, days 1,158
Discount survival,* days 1,324
Discount QA survival,* days 1,090
Medical costs, $
Initial year 16,641
Second year 1,970
Third year 1,737
Fourth year 1,819
Cumulative 4-yr costs 22,167
Cumulative discount* 4-yr costs 21,680
*Discount rate of 3% per year.CI confidence interval; QA quality adjusted.ost-effectiveness analyses. Cost-effectiveness ratios are not
resented as there were no significant differences in key
omponents of these ratios. In the disease-specific cost-
ffectiveness analysis, a ZES versus BMS treatment strategy
educed TVR with no difference in cumulative medical
osts. In the comprehensive cost-effectiveness analysis, a
ES versus BMS treatment strategy was associated with
onsignificant differences in discounted quality-adjusted
urvival and total medical costs. Figure 4 is a plot of 200
ootstrap samples for incremental discounted medical cost
ersus incremental discounted quality-adjusted survival for a
ES versus BMS treatment strategy.
iscussion
he use of ZES versus BMS was associated with a signif-
cant reduction in TVR through 4-year follow-up with no
ifference in death, nonfatal MI, quality-adjusted survival,
r total medical costs. These results are comparable to other
tudies of DES versus BMS. Subjects randomized to receive
ES versus BMS had higher index procedure costs with
imilar lengths of stay. However, subjects receiving BMS
Event Rates
p Value
Endeavor
(n  598)
Difference
(95% CI)
27.2 8.1 (0.9 to 15.4) 0.027
1.7 0.4 (1.9 to 1.1) 0.64
87.3 14.6 (3.5 to 32.8) 0.11
116.3 22.4 (1.8 to 43.1) 0.034
5.9 0.4 (0.2 to 1.0) 0.22
s
ndeavor
n  598)
Difference
(95% CI) p Value
1,406 1 (21 to 19) 0.93
1,162 4 (21 to 14) 0.68
1,325 1 (19 to 18) 0.94
1,093 3 (19 to 13) 0.69
17,422 781 (1,623 to 61) 0.069
1,709 261 (263 to 785) 0.33
1,405 332 (199 to 863) 0.22
1,337 481 (40 to 1,003) 0.070
21,873 294 (1,185 to 1,772) 0.70
21,483 198 (1,207 to 1,608) 0.78tayl Cost
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1185nderwent TVR procedures more frequently—ultimately
liminating total medical cost differences at 4-year follow-
p. This suggests a continuing benefit from ZES versus
MS that extends well beyond the first follow-up year and
ncourages clinical and economic analyses of DES versus
MS with a long-term perspective.
omparisons with other DES economic analyses. Two piv-
tal clinical trials—TAXUS IV (4) and SIRIUS (Sirolimus-
luting Stent in Coronary Lesion) (5)—evaluated DES
ersus BMS and published cost-effectiveness analyses. At
-year follow-up, our study and the other 2 reported higher
ndex procedure costs and lower follow-up period costs for
ubjects receiving DES versus BMS with cumulative 1-year
osts being higher for subjects receiving DES. In each of
hese studies, higher costs for DES versus BMS were the
rimary factor contributing to differences in index procedure
osts; whereas, lower repeat revascularization rates were the
rimary contributor to lower follow-up period costs for
tudy subjects receiving DES versus BMS. Differences in
epeat revascularizations drove between-trial differences in
isease-specific cost-effectiveness estimates; whereas, differ-
nces in total medical costs and estimated quality of life
rove between-trial differences in comprehensive cost-
ffectiveness estimates.
During the past 6 years, costs for BMS have remained
elatively constant; whereas, the costs for DES have de-
reased. The net effect of these changes is that the $2,000
nd $1,900 cost differentials for DES versus BMS reported
n the SIRIUS and TAXUS IV economic analyses were
educed to $1,200 by the time of the ENDEAVOR II
conomic analysis. This creates a $700 to $800 cost advan-
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Figure 2. 4-Year Cumulative Quality-Adjusted Survival
Four-year cumulative quality-adjusted survival according to randomization
to the Driver bare-metal stent versus the Endeavor drug-eluting stent.age for the ZES versus BMS comparison in the presenttudy that needs to be considered when assessing these
esults versus those from previous DES versus BMS eco-
omic analyses.
Previous researchers have suggested that differences in the
se of protocol-mandated coronary angiography may have
ontributed to between-trial differences in repeat revasculariza-
ion rates (4,9). Protocol-driven angiography rates were signif-
cantly higher for SIRIUS (66% of subjects) than for TAXUS
V (43%) or ENDEAVOR II (44%) (6,10,24). Of note, the
-month TVF rate for DES versus BMS was 7.9% versus
5.1% in ENDEAVOR II, 7.6% versus 14.4% in TAXUS IV,
nd 8.6% versus 21.0% in SIRIUS. Thus, it appears that
etween-trial differences in TVF results for DES versus BMS
re driven by differences in BMS event rates.
The absence of treatment-related survival differences in
he 3 trials of DES versus BMS magnified small differences
n total medical costs as quality-of-life adjustments were
pplied in disease-specific and comprehensive cost-
ffectiveness ratios. One-year total medical cost increments
or DES versus BMS were $309 in SIRIUS, $572 in
AXUS IV, and $781 in ENDEAVOR II. By 4-year
ollow-up, the choice of ZES versus BMS was associated
ith a $198 cost savings in ENDEAVOR II. Although it
ould be difficult to demonstrate a statistically significant
ifference between these values, comprehensive cost-
ffectiveness ratios magnified them to obtain values of
27,540 per QALY saved in SIRIUS and $47,798 in
AXUS IV. The 4-year comprehensive cost-effectiveness
atio for ENDEAVOR II was dominant (lower total
edical costs and better quality-adjusted survival). How-
ver, all of these ratios rely upon point estimates and do not
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Figure 3. 4-Year Cumulative Medical Costs
Four-year cumulative medical costs according to randomization to the
Driver bare-metal stent versus the Endeavor drug-eluting stent.
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1186ccount for the substantial variability inherent in medical
ost and QALY estimates.
egulator economic evaluation. A recent evaluation by the
nited Kingdom’s National Institute for Health and Clin-
cal Excellence concluded that DES are recommended for
he treatment of CAD only if, “the target artery to be
reated has less than a 3-mm caliber or the lesion is longer
han 15 mm, and the price difference between DES and
MS is no more than 300 pounds.” The 300-pound-price-
ifferential recommendation was based upon the results of
n economic model that assumed the greatest benefit from
VR reduction occurred in the first follow-up year and by
esign did not include follow-up after this point (25). Our
nalysis beyond the 1-year follow-up indicated that a
ignificant difference in TVR rates occurs during the 2- to
-year follow-up and demonstrated that the use of DES
ersus BMS is cost neutral with a $1,200 price differential.
ong-term economic attractiveness. The present study ex-
ends the follow-up period for DES versus BMS economic
nalysis from 1 year to 4 years. Other studies examined a
-year time frame because most target lesion-related clinical
vents occur during the first year in BMS clinical trials;
linical events after the first year are more likely related to
rogression of CAD and are not target lesion-related (26).
owever, our results demonstrate that the difference in
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Figure 4. Bootstrap Results: 4-Year Incremental Costs Versus 4-Year Quali
Bootstrap results for the 4-year cost-effectiveness ratio of the Endeavor drug-eVR rates between DES and BMS in ENDEAVOR II tontinued to evolve beyond the first year. This is particularly
mportant as very late stent thrombosis has attracted in-
reased scrutiny (3,27). In this regard, clinical and economic
omparisons between DES and BMS may resemble those
etween CABG and PCI in that their respective cumulative
ost and benefit curves may converge as repeat revascular-
zations occur more frequently in the less expensive treat-
ent strategy (28). It is therefore important to allow
ufficient time for longer-term events to occur when evalu-
ting technologies with different biological effects.
tudy limitations. This study has several limitations that are
argely related to study data collection methods. First, as
conomic and quality-of-life data were not collected pro-
pectively in ENDEAVOR II, we needed to rely upon
econdary sources for our medical cost and quality-of-life
eights. This limitation both muted the precision of our
nalyses and prevented certain cost elements (outpatient and
edication costs) from being included in our work. None-
heless, we believe that our results accurately reflect impor-
ant cost elements and cost drivers (stent costs and repeat
evascularization rates). The omission of dual antiplatelet
herapy costs will have a minimal effect upon this study’s
esults as subjects in both study arms were prescribed aspirin
ndefinitely and clopidogrel for 12 weeks. However, guide-
ines for the use of these therapies have changed since the
5 10 15 20 25
 Days Benefit
usted Survival Benefit
stent versus the Driver bare-metal stent.usted
ty-Adjime of this trial and may influence both the medical costs
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1187nd health benefits associated with the use of ZES versus
MS. Second, our study ended at 4 years and did not include
ifetime estimates of medical costs and quality-adjusted life
xpectancy. However, survival differences at 4 years were
egligible, and we do not believe that a lifetime analysis would
ave added substantial information to our results. Lastly, our
tudy is limited by the population of subjects enrolled in the
NDEAVOR II clinical trial. Although we believe that our
esults accurately reflect long-term clinical and economic out-
omes within this population, they may not be transferable to
atients in other populations.
onclusions
ercutaneous coronary intervention with ZES versus BMS
s associated with significant reductions in TVR through
-year follow-up. The resulting medical cost savings are
ufficient to fully cover the additional costs of DES. These
esults are comparable to those for other studies evaluating
ES versus BMS.
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